Stereotactic radiotherapy for treatment of cavernous sinus meningiomas
Selch MT,    International Journal of Radiation Oncology*Biology*Physics   01 May 2004 (Vol. 59, Issue 1, Pages 101-111)
meningioma_cavernous_srs_selch.jpg (35782 bytes) Picture on left:


(a) Axial T1-weighted contrast-enhanced planning MRI of 24.62-cm3 cavernous sinus meningioma in a 51-year-old woman. Tumor was treated with 12 noncoplanar fields and received 4860 cGy prescribed at the 90% isodose line. (b) Axial T1-weighted contrast-enhanced follow-up MRI of tumor 12 months after stereotactic radiotherapy completion demonstrating response.

Despite significant advances in neuroimaging and microsurgical techniques, meningiomas of the cavernous sinus continue to represent a neurosurgical challenge. The preoperative assessment demonstrates total encasement or narrowing of the intracavernous portion of the internal carotid artery in 63% of patients. Furthermore, although the microscopic appearance of meningioma is typically benign, careful histopathologic analysis has demonstrated infiltration of adjacent vascular structures and cranial nerves by cavernous sinus lesions. Consequently, the reported rates of gross total resection for cavernous sinus meningiomas vary from 12% to 84%. Local recurrence is reported in 9.6–25% of patients despite confirmed total resection of cavernous sinus meningioma on imaging. Local progression is even more frequent after subtotal removal of meningioma. In a series of 119 cavernous sinus meningiomas, DeJesus reported a 5-year relapse-free survival rate of 81% after complete resection compared with 62% after incomplete tumor removal. Attempted removal of cavernous sinus meningiomas has been associated with serious morbidity. The rate of exacerbation or induction of cranial neuropathy resulting from cavernous sinus surgery varies from 6% to 18%. In addition, hemorrhage and cerebrospinal fluid leak have been reported in 5% and 21%, respectively.

Conventional external beam radiotherapy (RT) has been demonstrated to be an effective adjunctive therapy after subtotal resection of intracranial meningioma and a useful primary treatment modality for unresectable or inoperable tumors. Several authors have demonstrated relapse-free survival rates after external beam RT for cavernous sinus meningiomas that equal or exceed the rates achieved by radical resection). External beam RT, however, may occasionally produce long-term optic, pituitary, or cognitive dysfunction

Stereotactic radiosurgery (SRS) is a method for delivering a large, single dose of radiation to an intracranial site. The inherently steep dose gradient produced by SRS affords physical protection of the normal tissue adjacent to the target lesion. SRS has proved effective for a variety of benign central nervous system disorders, including meningiomas. Local control rates of 86–100% have been reported after either gamma-knife or linear accelerator-based SRS for selected patients with cavernous sinus meningiomas

Despite the dosimetric advantages of SRS, use of this technique for cavernous sinus meningiomas has resulted in a 1.5–10.5% serious morbidity rate, predominantly affecting the cranial nerves. Morbidity after SRS is strongly associated with the tumor volume and location). For these reasons, application of SRS to cavernous sinus meningiomas has generally been restricted to tumors <3 cm in greatest dimension and located several millimeters from the optic apparatus.

Stereotactic RT (SRT) combines the physical dose localization advantages of SRS with the radiobiologic benefits of dose fractionation. Unlike SRS, the treatment planning fiducial system and patient immobilization device can be applied noninvasively. The accuracy of patient repositioning during SRT has been documented. A total fractionated dose of ionizing radiation, known from conventional RT experience to be effective for meningioma and tolerated by the central nervous system, can be delivered by the SRT technique. SRT has proved safe and efficacious for a variety of skull base tumors, including meningiomas. We report the results of SRT using a dedicated linear accelerator equipped with a micromultileaf collimator (MMLC) for 45 patients with meningiomas of the cavernous sinus. Most of the patients had tumors considered ineligible for treatment by SRS.

To assess the safety and efficacy of stereotactic radiotherapy (SRT) using a linear accelerator equipped with a micromultileaf collimator for cavernous sinus meningiomas.

Methods and materials

Forty-five patients with benign cavernous sinus meningiomas were treated with SRT between November 1997 and April 2002. Sixteen patients received definitive treatment on the basis of imaging characteristics of the cavernous sinus tumor. Twenty-nine patients received SRT either as immediate adjuvant treatment after incomplete resection or at documented recurrence. Treatment planning in all patients included CT–MRI image fusion and beam shaping using a micromultileaf collimator. The primary tumor volume varied from 1.41 to 65.66 cm3 (median, 14.5 cm3). The tumor diameter varied from 1.4 to 7.4 cm (median, 3.8 cm). Tumor compressed the optic chiasm or optic nerve in 30 patients. All tumors were treated with a single isocenter plus a margin of normal parenchyma varying from 1 to 5 mm (median, 2.5 mm). The prescribed dose varied from 4250 to 5400 cGy (median, 5040 cGy). The prescription isodose varied from 87% to 95% (median, 90%). The maximal tumor dose varied from 5000 to 6000 cGy (median, 5600 cGy). The specificity of SRT plans was further evaluated using the homogeneity index (HI), defined as the ratio of the maximal target dose to the prescription dose. The median HI was 1.11 (range, 1.05–1.15). The daily and total dose to the optic apparatus was restricted to 200 cGy and 5040 cGy, respectively. As a consequence, the total prescribed target dose varied from 4250–5400 cGy (median, 5040 cGy). Twenty-two patients received 5040 cGy. The maximal dose varied from 5000 to 6000 cGy (median, 5600 cGy). The fraction size varied from 170 to 180 cGy. Forty-three patients received 180 cGy/day. The follow-up varied from 12 to 53 months (median, 36 months).

Results

The actuarial 3-year overall and progression-free survival rate was 100% and 97.4%, respectively. One patient (2%) developed local relapsed at 18 months. A partial imaging response occurred in 18% of patients, and the tumor was stable in the remaining 80%. Preexisting neurologic complaints improved in 20% of patients and were stable in the remainder. No patient, tumor, or treatment factors were found to be predictive of imaging or clinical response. Transient acute morbidities included headache responsive to nonnarcotic analgesics in 4 patients, fatigue in 3 patients, and retroorbital pain in 1 patient. No treatment-induced peritumoral edema, cranial neuropathy, endocrine dysfunction, cognitive decline, or second malignancy occurred. One patient had an ipsilateral cerebrovascular accident 6 months after SRT.

Conclusion

Stereotactic radiotherapy is both safe and effective for patients with cavernous sinus meningiomas. Field shaping using a micromultileaf collimator allows conformal and homogeneous radiation of cavernous sinus meningiomas that may not be amenable to single-fraction stereotactic radiosurgery because of tumor size or location. Additional clinical experience is necessary to determine the position of SRT among the available innovative fractionated RT options for challenging skull base meningiomas.

meningioma_cavernous_srs_selch_table.gif (27415 bytes)